KA-1874 / KYinno - LARVOL DELTA

Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity (AACR 2023) - "In cell-based luciferase reporter assays, KA-1874 blocks PVRIG and TIGIT-mediated inhibitory signaling and enhances CD3 signaling with EC50 of 1.1nM and 1.4nM respectively, while COM701 against PVRIG and EOS488 against TIGIT both with EC50 above 2nM. In comparison, KA-1874 or pembrolizumab alone fails to inhibit tumor growth. The above results indicate KA-1874 is an excellent candidate therapeutical antibody for cancer immunotherapy."

Oncology • NECTIN2 • PD-1 • PVR • TIGIT